CHIKV infection
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Voluntarily signed informed consent; 2.Age>=18 years old, male or female; 3.Including recent travel to chikungunya-endemic areas, places of residence or work, chikungunya fever cases, fever, muscular and osteoarthralgia, headache and rash, living in chikungunya-endemic areas or travel to endemic areas within 12 days, and history of mosquito bites within 12 days before the onset of symptoms; 4.The laboratory diagnosis criteria are consistent with the clinical case of chikungunya fever, positive detection of chikungunya virus nucleic acid, or positive chikungunya virus antibody, or isolation of virus, or the titer of serum-specific IgG antibodies in the convalescent phase is more than 4 times higher than that in the acute phase; 5.Subject is voluntary and able to comply with all requirements specified in the study protocol.
Exclusion criteria
Exclusion criteria: 1.suspected focal infection; 2.Subject has other pre-existing medical conditions that may preclude compliance with the various evaluation plans in the treatment protocol, or may interfere with the observation of the efficacy or safety of this study (e.g., current malignancy, uncontrolled seizures, severe psychiatric illness, active tuberculosis currently being treated, etc.); 3.Age < 18 years, pregnant women; 4.Patients who are judged by the investigator to be unsuitable to participate in this trial;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subjects' Clinical Characteristics, Virological Characteristics, and Immunological Characteristics; | — |
Secondary
| Measure | Time frame |
|---|---|
| Subjects' chronic arthropathies and joint sequelae at 1 month, 2 months, and 6 months post-discharge.;Safety indicators during follow-up, including the incidence of adverse events and abnormal clinical laboratory findings.; | — |
Countries
China
Contacts
The First People's Hospital of Foshan